EP4041245A4 - Therapeutische formulierungen und verwendungen davon - Google Patents

Therapeutische formulierungen und verwendungen davon Download PDF

Info

Publication number
EP4041245A4
EP4041245A4 EP20883598.3A EP20883598A EP4041245A4 EP 4041245 A4 EP4041245 A4 EP 4041245A4 EP 20883598 A EP20883598 A EP 20883598A EP 4041245 A4 EP4041245 A4 EP 4041245A4
Authority
EP
European Patent Office
Prior art keywords
therapeutic formulations
formulations
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20883598.3A
Other languages
English (en)
French (fr)
Other versions
EP4041245A1 (de
Inventor
Douglas I. Hepler
Gail L. DEMPSEY
Roland Johnson
Michael Kelly
Michael Daniel
Neil E. Paulsen
Bert CLAYTON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dechra Veterinary Products LLC
Original Assignee
Piedmont Animal Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piedmont Animal Health Inc filed Critical Piedmont Animal Health Inc
Priority to EP23174724.7A priority Critical patent/EP4233854A3/de
Publication of EP4041245A1 publication Critical patent/EP4041245A1/de
Publication of EP4041245A4 publication Critical patent/EP4041245A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP20883598.3A 2019-11-01 2020-10-29 Therapeutische formulierungen und verwendungen davon Pending EP4041245A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP23174724.7A EP4233854A3 (de) 2019-11-01 2020-10-29 Therapeutische formulierungen und verwendungen davon

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962929631P 2019-11-01 2019-11-01
PCT/US2020/057899 WO2021087074A1 (en) 2019-11-01 2020-10-29 Therapeutic formulations and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP23174724.7A Division EP4233854A3 (de) 2019-11-01 2020-10-29 Therapeutische formulierungen und verwendungen davon
EP23174724.7A Division-Into EP4233854A3 (de) 2019-11-01 2020-10-29 Therapeutische formulierungen und verwendungen davon

Publications (2)

Publication Number Publication Date
EP4041245A1 EP4041245A1 (de) 2022-08-17
EP4041245A4 true EP4041245A4 (de) 2023-12-13

Family

ID=75715592

Family Applications (2)

Application Number Title Priority Date Filing Date
EP20883598.3A Pending EP4041245A4 (de) 2019-11-01 2020-10-29 Therapeutische formulierungen und verwendungen davon
EP23174724.7A Pending EP4233854A3 (de) 2019-11-01 2020-10-29 Therapeutische formulierungen und verwendungen davon

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP23174724.7A Pending EP4233854A3 (de) 2019-11-01 2020-10-29 Therapeutische formulierungen und verwendungen davon

Country Status (6)

Country Link
EP (2) EP4041245A4 (de)
JP (1) JP2023501207A (de)
CN (2) CN118750482A (de)
AU (1) AU2020375825A1 (de)
CA (1) CA3156590A1 (de)
WO (1) WO2021087074A1 (de)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
US20040204471A1 (en) * 2003-03-20 2004-10-14 Pharmacia Corporation Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents
US20050070543A1 (en) * 2003-07-11 2005-03-31 Pharmacia Corporation Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage
US20140256804A1 (en) * 2011-10-18 2014-09-11 Raqualia Pharma Inc. Pharmaceutical composition
US20190142789A1 (en) * 2017-08-09 2019-05-16 Piedmont Animal Health, Llc Therapeutic formulations and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9804886D0 (en) * 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
US20040138296A1 (en) * 2002-08-12 2004-07-15 Pharmacia Corporation Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
GT200600396A (es) * 2005-09-07 2007-04-23 Dispositivos para la aplicacion de medicamentos transdermicos conteniendo o-desmetil venlafaxina (odv) o sus sales
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
CA2922330A1 (en) * 2013-09-12 2015-03-19 Laboratorios Del Dr. Esteve, S.A. Nsaid and sigma receptor ligand combinations
US9763912B2 (en) * 2013-10-30 2017-09-19 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions, methods of use, and methods of treatment
WO2015127416A1 (en) * 2014-02-24 2015-08-27 Urigen Pharmaceuticals, Inc. Compositions of pentosan polysulfate salts for oral administration and methods of use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
US20040204471A1 (en) * 2003-03-20 2004-10-14 Pharmacia Corporation Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents
US20050070543A1 (en) * 2003-07-11 2005-03-31 Pharmacia Corporation Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage
US20140256804A1 (en) * 2011-10-18 2014-09-11 Raqualia Pharma Inc. Pharmaceutical composition
US20190142789A1 (en) * 2017-08-09 2019-05-16 Piedmont Animal Health, Llc Therapeutic formulations and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021087074A1 *
ZARGHI AFSHIN ET AL: "Design, Synthesis, and Biological Evaluation of New 2-Phenyl-4H-chromen-4-one Derivatives as Selective Cyclooxygenase-2 Inhibitors", SCIENTIA PHARMACEUTICA, vol. 83, no. 1, 1 January 2015 (2015-01-01), Austria, pages 15 - 26, XP055932699, ISSN: 0036-8709, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727773/pdf/SciPharm-83-15.pdf> DOI: 10.3797/scipharm.1407-20 *

Also Published As

Publication number Publication date
CA3156590A1 (en) 2021-05-06
EP4233854A3 (de) 2024-01-17
JP2023501207A (ja) 2023-01-18
EP4041245A1 (de) 2022-08-17
EP4233854A2 (de) 2023-08-30
WO2021087074A1 (en) 2021-05-06
CN114728014A (zh) 2022-07-08
CN118750482A (zh) 2024-10-11
AU2020375825A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
EP4045480A4 (de) Pharmazeutische formulierungen
EP3706741A4 (de) Pharmazeutische zusammensetzung und verwendung davon
EP4003401A4 (de) Zusammensetzungen und verfahren mit proteaseaktivierten therapeutika
EP3946320A4 (de) Hsp90-bindende konjugate und formulierungen davon
EP3638251A4 (de) Bisphosphocingelformulierungen und verwendungen davon
EP3740576A4 (de) Therapeutische zusammensetzungen und verfahren zur herstellung und verwendung davon
EP4034159A4 (de) Neoglycokonjugate als impfstoffe und therapeutische werkzeuge
EP3980009A4 (de) Modifizierte freisetzungsformulierungen und deren verwendung
EP3917910A4 (de) Therapeutische verbindungen und zusammensetzungen
EP3873444A4 (de) Therapeutische verbindungen und zusammensetzungen
EP3746078A4 (de) Orale formulierungen und verwendungen davon
EP4110066A4 (de) Formulierungen und deren verwendungen
EP4011898A4 (de) 2-hydroxy-5-pregnan-20-on-derivate und verwendung davon
EP3773670A4 (de) Hsp90-targeting-konjugate und formulierungen davon
EP3851121A4 (de) Pharmazeutische zusammensetzung mit menschlichen monoklonalen anti-il-33-antikörpern
EP4031520A4 (de) Bildgebungs- und therapeutische zusammensetzungen
EP3760616A4 (de) 4-methyldihydropyrimidinonverbindung und medizinische verwendung davon
EP4007590A4 (de) Dihydrohonokiol enthaltende formulierungen
EP4013445A4 (de) Therapeutische proteinzusammensetzungen und verfahren
EP3873446A4 (de) Therapeutische verbindungen und zusammensetzungen
EP3999056A4 (de) Pharmazeutische kombination und verwendung davon
EP3980008A4 (de) Formulierungen mit verzögerter freisetzung und verwendung davon
EP3919472A4 (de) Dezocinderivat und medizinische verwendung davon
EP3915978A4 (de) N-benzyl-n-arylsulfonamidderivate, ihre herstellung und verwendung
EP3843742A4 (de) Cd73-inhibitoren und deren therapeutische verwendungen

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220427

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031600000

Ipc: A61K0009000000

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 29/00 20060101ALI20230803BHEP

Ipc: A61K 31/485 20060101ALI20230803BHEP

Ipc: A61K 31/352 20060101ALI20230803BHEP

Ipc: A61K 47/12 20060101ALI20230803BHEP

Ipc: A61K 47/10 20170101ALI20230803BHEP

Ipc: A61K 9/20 20060101ALI20230803BHEP

Ipc: A61K 9/08 20060101ALI20230803BHEP

Ipc: A61K 9/00 20060101AFI20230803BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20231109

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 29/00 20060101ALI20231103BHEP

Ipc: A61K 31/485 20060101ALI20231103BHEP

Ipc: A61K 31/352 20060101ALI20231103BHEP

Ipc: A61K 47/12 20060101ALI20231103BHEP

Ipc: A61K 47/10 20170101ALI20231103BHEP

Ipc: A61K 9/20 20060101ALI20231103BHEP

Ipc: A61K 9/08 20060101ALI20231103BHEP

Ipc: A61K 9/00 20060101AFI20231103BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DECHRA VETERINARY PRODUCTS, LLC